Top

Skeletal Radiology

Published in:

01-05-2009 | Scientific Article

Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions

Authors: Rong Tian, Minggang Su, Ye Tian, Fanglan Li, Lin Li, Anren Kuang, Jiancheng Zeng

Published in: Skeletal Radiology | Issue 5/2009

Abstract

Purpose

The purpose of the present study was to evaluate whether 2-fluoro[fluorine-18]-2-deoxy-d-glucose (F-18 FDG) positron emission tomography (PET) could differentiate malignant and benign bone lesions and whether obtaining delayed F-18 FDG PET images could improve the accuracy of the technique.

Methods

In a prospective study, 67 patients with bone lesions detected by computed tomography (CT) or magnetic resonance imaging were included. Whole body PET/CT imaging was performed at 1 h (early) after the F-18 FDG injection and delayed imaging at 2 h post injection was performed only in the abnormal region. Semiquantitative analysis was performed using maximum standardized uptake value (SUV_max), obtained from early and delayed images (SUV_maxE and SUV_maxD, respectively). The retention index (RI) was calculated according to the equation: RI = (SUV_maxD − SUV_maxE) × 100/SUV_maxE. Histopathology of surgical specimens and follow-up data were used as reference criteria. The SUV_maxE and RI were compared between benign and malignant lesions.

Results

The final diagnoses revealed 53 malignant bone lesions in 37 patients and 45 benign lesions in 30 patients. There were statistically significant differences in the SUV_maxE between the malignant and benign lesions (P = 0.03). The mean SUV_maxE was 6.8 ± 4.7 for malignant lesions and 4.5 ± 3.3 for benign lesions. However, a considerable overlap in the SUV_maxE was observed between some benign and malignant tumors. With a cutoff value of 2.5 for the SUV_maxE, the sensitivity, specificity, and accuracy were 96.0%, 44.0%, and 72.4%, respectively. The positive predictive value (PPV) and negative predictive value (NPV) were 67.1% and 90.9%, respectively. There were significant differences in the RI between the malignant and benign lesions (P = 0.004). But there was overlap between the two groups. The mean RI was 7 ± 11 for the benign lesions and 18 ± 11 for the malignant lesions. When an RI of 10 was used as the cutoff point, the sensitivity, specificity, and accuracy were 90.6%, 76.0%, and 83.7.0%, respectively. The PPV and NPV were 81.4% and 87.1%, respectively.

Conclusions

The results of this study indicate that dual-time point F-18 FDG PET may provide more help in the differentiation of malignant tumors from benign ones.

Erlemann R. MRI is highly sensitive for the detection of bone marrow abnormalities, cortical destruction or soft tissue tumors adjacent or infiltrating neighboring bones. Eur J Radiol 2006; 58(1): 48–67.PubMedCrossRef

Hillner BE, Siegel BA, Shields AF, et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the National Oncologic PET Registry. J Nucl Med 2008; 49(12): 1928–1935.PubMedCrossRef

Kim SK, Allen-Auerbach M, Goldin J, et al. Accuracy of PET/CT in characterization of solitary pulmonary lesions. J Nucl Med 2007; 48(2): 214–220.PubMed

Dimitrakopoulou-Strauss ASL, Heichel T, Wu H, Burger C, Bernd L, Ewerbeck V. The role of quantitative ¹⁸F-FDG PET studies for the differentiation of malignant and benign bone lesions. J Nucl Med 2002; 43(4): 510–518.PubMed

Kern KA, Brunetti A, Norton JA, et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 1988; 29(2): 181–186.PubMed

Adler LP, Blair HF, Makley JT, et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991; 32(8): 1508–1512.PubMed

Griffeth LK, Dehdashti F, McGuire AH, et al. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-d- glucose. Radiology 1992; 182(1): 185–194.PubMed

Dehdashti FSB, Griffeth LK, Fusselman MJ, Trask DD, McGuire AH. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-d-glucose. Radiology 1996; 200(1): 243–247.PubMed

Aoki J, Watanabe H, Shinozaki T, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology 2001; 219(3): 774–777.PubMed

10.

Kole AC, Nieweg OE, Hoekstra HJ, van Horn JR, Koops HS, Vaalburg W. Fluorine-18-fluorodeoxyglucose assessment of glucose metabolism in bone tumors. J Nucl Med 1998; 39(5): 810–815.PubMed

11.

Schulte M, Brecht-Krauss D, Heymer B, et al. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J Nucl Med 2000; 41(10): 1695–1701.PubMed

12.

Zhuang H, Pourdehnad M, Lambright ES, et al. Dual time point ¹⁸F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001; 42(9): 1412–1417.PubMed

13.

Lan XL, Zhang YX, Wu ZJ, Jia Q, Wei H, Gao ZR. The value of dual time point ¹⁸F-FDG PET imaging for the differentiation between malignant and benign lesions. Clinical radiology 2008; 63(7): 756–764.PubMedCrossRef

14.

Matthies A, Hickeson M, Cuchiara A, Alavi A. Dual time point ¹⁸F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002; 43(7): 871–875.PubMed

15.

Ma S-Y, See L-C, Lai C-H, et al. Delayed ¹⁸F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients. J Nucl Med 2003; 44(11): 1775–1783.PubMed

16.

Mavi A, Urhan M, Yu JQ, et al. Dual time point ¹⁸F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med 2006; 47(9): 1440–1446.PubMed

17.

Xiu Y, Bhutani C, Dhurairaj T, et al. Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity. Clin Nucl Med 2007; 32(2): 101–105.PubMedCrossRef

18.

Sahlmann CO, Siefker U, Lehmann K, Meller J. Dual time point 2-[18F]fluoro-2′-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis. Nucl Med Commun 2004; 25(8): 819–823.PubMedCrossRef

19.

Daisuke U, Shinya S, Masanori I, et al. Added value of SPECT/CT fusion in assessing suspected bone metastasis: comparison with scintigraphy alone and nonfused scintigraphy and CT. Radiology 2005; 238(11): 264–271.

20.

Shin DS, Shon OJ, Han DS, Choi JH, Chun KA, Cho IH. The clinical efficacy of ¹⁸F-FDG-PET/CT in benign and malignant musculoskeletal tumors. Ann Nucl Med 2008; 22(7): 603–609.PubMedCrossRef

21.

Aoki J, Endo K, Watanabe H, Shinozaki T, Yanagawa T, Ahmed AR, et al. FDG-PET for evaluating musculoskeletal tumors. J Orthop Sci 2003; 8(3): 435–441.PubMedCrossRef

22.

Feldman F, Heertum RV, Manus C. ¹⁸FDG PET scanning of benign and malignant musculoskeletal lesions. Skeletal Radiol 2003; 32: 201–208.PubMed

23.

Meszaros K, Lang CH, Bagby GJ, Spitzer JJ. Contribution of different organs to increased glucose consumption after endotoxin administration. J Biol Chem 1987; 262(23): 10965–10970.PubMed

24.

Strobel K, Bode B, Lardinois D, Exner U. PET-positive fibrous dysplasia—a potentially misleading incidental finding in a patient with intimal sarcoma of the pulmonary artery. Skeletal Radiology 2007; 36: 24–28.CrossRef

25.

Conill C, Setoain X, Colomo L, et al. Diagnostic efficacy of bone scintigraphy, magnetic resonance imaging, and positron emission tomography in bone metastases of myxoid liposarcoma. J Magn Reson Imaging 2008; 27(3): 625–628.PubMedCrossRef

26.

Goo JM, Im J-G, Do K-H, et al. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 2000; 216(1): 117–121.PubMed

27.

Knight SB, Delbeke D, Stewart JR, Sandler MP. Evaluation of pulmonary lesions with FDG-PET: comparison of findings in patients with and without a history of prior malignancy. Chest 1996; 109(4): 982–988.PubMedCrossRef

28.

Bredella MA, Essary B, Torriani M, Ouellette HA, Palmer WE. Use of FDG-PET in differentiating benign from malignant compression fractures. Skeletal Radiol 2008; 37(5): 405–413.PubMedCrossRef

29.

Hustinx R, Smith RJ, Benard F, Rosenthal DI, Machtay M, Farber LA, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 1999; 26(10): 1345–1348.PubMedCrossRef

30.

Yoshihiro N, Yuka Y, Naruhide K, Shinya I, Yasuhiro S, Ohkawa M. Dual-time-point FDG-PET for evaluation of lymph node metastasis in patients with non-small-cell lung cancer. Ann Nucl Med 2008; 22: 245–250.CrossRef

31.

Hamada K, Tomita Y, Ueda T, et al. Evaluation of delayed ¹⁸F-FDG PET in differential diagnosis for malignant soft-tissue tumors. Ann Nucl Med 2006; 20(10): 671–675.PubMedCrossRef

32.

Strobel K, Exner UE, Stumpe KD, Hany TF, Bode B, Mende K, et al. The additional value of CT images interpretation in the differential diagnosis of benign vs. malignant primary bone lesions with ¹⁸F-FDG-PET/CT. Eur J Nucl Med Mol Imaging 2008; 35(11): 2000–2008.PubMedCrossRef

Title: Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions
Authors: Rong Tian
Minggang Su
Ye Tian
Fanglan Li
Lin Li
Anren Kuang
Jiancheng Zeng
Publication date: 01-05-2009
Publisher: Springer-Verlag
Published in: Skeletal Radiology / Issue 5/2009
Print ISSN: 0364-2348
Electronic ISSN: 1432-2161
DOI: https://doi.org/10.1007/s00256-008-0643-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2009

A 5-year-old with abnormal hand and forearm

Power Doppler ultrasound of rheumatoid synovitis: quantification of vascular signal and analysis of interobserver variability

Prediction of erosion progression using ultrasound in established rheumatoid arthritis: a 2-year follow-up study

A 5-year-old with abnormal hand and forearm: diagnosis and discussion

Synovial fold of the posterior shoulder joint capsule

Magnetic resonance image segmentation using semi-automated software for quantification of knee articular cartilage—initial evaluation of a technique for paired scans